Definium Therapeutics, Inc. (DFTX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Definium Therapeutics, Inc. (DFTX) has a cash flow conversion efficiency ratio of -0.104x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-95.41 Million) by net assets ($918.68 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see DFTX market cap for the company's overall valuation and market capitalisation.
Definium Therapeutics, Inc. - Cash Flow Conversion Efficiency Trend (2015–2025)
This chart illustrates how Definium Therapeutics, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Definium Therapeutics, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Definium Therapeutics, Inc. ranked by their cash flow conversion efficiency. See Definium Therapeutics, Inc. cash flow to debt ratio to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sulzer AG
SW:SUN
|
0.043x |
|
EPAM Systems Inc
NYSE:EPAM
|
-0.001x |
|
UPL Limited
NSE:UPL
|
-0.117x |
|
APT Medical Inc
SHG:688617
|
0.098x |
|
CHINA TOWER UNSP.ADR/100
F:2Y10
|
N/A |
|
Zhejiang Crystal Optech Co Ltd
SHE:002273
|
0.032x |
|
Bilibili Inc
NASDAQ:BILI
|
0.128x |
|
Corporacion Financiera Alba SA
MC:ALB
|
0.006x |
Annual Cash Flow Conversion Efficiency for Definium Therapeutics, Inc. (2015–2025)
The table below shows the annual cash flow conversion efficiency of Definium Therapeutics, Inc. from 2015 to 2025. View DFTX share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $332.33 Million | $-131.56 Million | -0.396x | -20.79% |
| 2024-12-31 | $241.45 Million | $-79.13 Million | -0.328x | +60.22% |
| 2023-12-31 | $78.13 Million | $-64.36 Million | -0.824x | -147.95% |
| 2022-12-31 | $150.92 Million | $-50.14 Million | -0.332x | -9.96% |
| 2021-12-31 | $151.66 Million | $-45.82 Million | -0.302x | +2.86% |
| 2020-12-31 | $75.87 Million | $-23.60 Million | -0.311x | -309.18% |
| 2019-12-31 | $2.74 Million | $-208.12K | -0.076x | +62.91% |
| 2018-12-31 | $3.52 Million | $-722.45K | -0.205x | -21.47% |
| 2017-12-31 | $3.95 Million | $-665.98K | -0.169x | +19.37% |
| 2016-12-31 | $127.28K | $-26.64K | -0.209x | -27.73% |
| 2015-12-31 | $284.17K | $-46.56K | -0.164x | -- |
About Definium Therapeutics, Inc.
Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company's lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a cli… Read more